HPV vaccine might be a cost-effective barrier to oropharyngeal cancer in males

2015 ◽  
Vol 29 (35) ◽  
pp. 14-14
Keyword(s):  
Oropharyngeal Cancer ◽  
Hpv Vaccine ◽  
Cost Effective ◽  
Effective Barrier

scholarly journals An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chengxue Zhong ◽  
Li Xu ◽  
Ho-Lan Peng ◽  
Samantha Tam ◽  
Li Xu ◽  
...  
Keyword(s):  
Public Health ◽  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Hpv Vaccine ◽  
Health Benefits ◽  
Incidence Rates ◽  
Vaccine Uptake ◽  
Males And Females ◽  
Quality Adjusted Life ◽  
The U.S

AbstractIn 2017, 46,157 and 3,127 new oropharyngeal cancer (OPC) cases were reported in the U.S. and Texas, respectively. About 70% of OPC were attributed to human papillomavirus (HPV). However, only 51% of U.S. and 43.5% of Texas adolescents have completed the HPV vaccine series. Therefore, modeling the demographic dynamics and transmission of HPV and OPC progression is needed for accurate estimation of the economic and epidemiological impacts of HPV vaccine in a geographic area. An age-structured population dynamic model was developed for the U.S. state of Texas. With Texas-specific model parameters calibrated, this model described the dynamics of HPV-associated OPC in Texas. Parameters for the Year 2010 were used as the initial values, and the prediction for Year 2012 was compared with the real age-specific incidence rates in 23 age groups for model validation. The validated model was applied to predict 100-year age-adjusted incidence rates. The public health benefits of HPV vaccine uptake were evaluated by computer simulation. Compared with current vaccination program, increasing vaccine uptake rates by 50% would decrease the cumulative cases by 4403, within 100 years. The incremental cost-effectiveness ratio of this strategy was $94,518 per quality-adjusted life year (QALY) gained. Increasing the vaccine uptake rate by 50% can: (i) reduce the incidence rates of OPC among both males and females; (ii) improve the quality-adjusted life years for both males and females; (iii) be cost-effective and has the potential to provide tremendous public health benefits in Texas.

scholarly journals High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ze-Hao Ye ◽  
Zhao-Zhen Liu ◽  
Si-Tong Cui ◽  
Zhen-Xing Chu ◽  
Yong-Jun Jiang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Cost Effective ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Acceptability ◽  
Cross Sectional ◽  
Sex With Men

Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P > 0.05). The prevalence of high-risk HPV among participants aged <30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.

scholarly journals Single dose nonavalent HPV vaccine – need of the hour

2020 ◽  
Vol 10 (2) ◽  
pp. 871-873
Author(s):  
Soma Bandyopadhyay ◽  
Manidip Pal
Keyword(s):  
Single Dose ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
Cost Effective ◽  
Quadrivalent Vaccine ◽  
Carcinoma Cervix ◽  
Long Term Follow Up

HPV vaccination of the 9-14 years girl children is the answer to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single dose HPV vaccination, antibody titre remains good. Herd immunity also achieved by HPV vaccine. Hence single dose nonavalent HPV vaccination of mass people (sexually naive 9-14 years girl children) can provide almost 100% protections and this will be cost-effective also for developing country.  

scholarly journals Knowledge of Human Papillomavirus (HPV) and Oropharyngeal Cancer and Acceptability of the HPV Vaccine among Dental Students

2020 ◽  
Vol 21 (12) ◽  
pp. 3595-3603
Author(s):  
Nada J Farsi ◽  
Sarah Al Sharif ◽  
Marwah Al Qathmi ◽  
Mazin Merdad ◽  
Hani Marzouki ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Hpv Vaccine ◽  
Dental Students

scholarly journals A video-based behavioural intervention associated with improved HPV knowledge and intention to vaccinate

2021 ◽  
Author(s):  
Sarah Marshall ◽  
Anne C Moore ◽  
Aoife Fleming ◽  
Laura Sahm
Keyword(s):  
Hpv Vaccine ◽  
Cost Effective ◽  
Knowledge Assessment ◽  
Feasibility Trial ◽  
Behavioural Intervention ◽  
Evidence Based ◽  
Baseline Knowledge ◽  
Effective Cost ◽  
Randomised Controlled ◽  
The Impact

Aims: The aim of this study was to design, develop and evaluate a theory and evidence-based intervention to improve human papillomavirus (HPV) and HPV vaccine knowledge, and intention to vaccinate, among parent-daughter dyads. Methods: A theory and evidence-based online behavioural intervention, "Is the HPV vaccine for me?" was developed to improve HPV and HPV vaccine knowledge, and intention to vaccinate. The impact and feasibility of the intervention was evaluated in a prospective randomised controlled feasibility trial. Results: A total of 49 parent-daughter dyads completed baseline knowledge assessment (n=24 control, n=25 intervention), and 35 dyads completed knowledge assessment at week 2 (n=17 control, n=18 intervention). The intervention was associated with a statistically significant increase in HPV, and HPV vaccine knowledge and intention to vaccinate. All intervention participants found the video interesting, while 96% found it useful. Conclusions: This intervention was found to be affordable, practicable, effective (cost-effective), acceptable, safe, and equitable, in this feasibility study.

The Role of the Dental Community in Oropharyngeal Cancer Prevention Through HPV Vaccine Advocacy

2019 ◽  
Author(s):  
Thomas Luke Arnell ◽  
Collin York ◽  
Alexis Nadeau ◽  
Maeve Lauren Donnelly ◽  
Laura Till ◽  
...  
Keyword(s):  
Cancer Prevention ◽  
Oropharyngeal Cancer ◽  
Hpv Vaccine
Sign in / Sign up

Export Citation Format

Share Document